INTRODUCTIONAcne has approximately an 85-90% lifetime prevalence, however the duration of the condition is not well characterized.1,2 Understanding the duration of the disease and healthcare utilization for the disease can…

INTRODUCTION Topical therapy is the most common way to administer acne medication1 and in cases of mild to moderate acne, it is the standard route of treatment.2 There is an…

INTRODUCTIONIsotretinoin is indicated for treating severe recalcitrant nodular acne; approved dosage of 1 mg/kg/d is typically prescribed for 20 weeks to achieve a cumulative dose of 120 mg/kg to 150…

INTRODUCTION Currently systemic antibiotics are indicated in the treatment of mild-to-moderate papulopustular acne, severe papulopustular /moderate nodular acne, and severe nodular /conglobate acne in combination with retinoids and/or topical benzoyl…

INTRODUCTIONAcne vulgaris is a multifactorial skin disorder affecting the pilosebaceous unit. The main factors involved in its pathogenesis include follicular hyperkeratinization, sebum overproduction, Propionibacterium acnes (P. acnes) over proliferation, inflammation…

INTRODUCTION A subset of patients with rosacea developed papules and pustules (PPR), which are currently viewed to be inflammatory follicular lesions.1,2 While recent studies employing gene array profiles, immunohistochemical and…

INTRODUCTIONAcne vulgaris and rosacea can have a profound impact on health-related quality of life (HRQL). A joint project by the American Academy of Dermatology Association and the Society for Investigative…

INTRODUCTION Rosacea is a chronic inflammatory skin disorder that most commonly presents with transient or persistent erythema in the central facial region with additional cutaneous symptoms including telangiectasia, papules and…

INTRODUCTIONAcne vulgaris is one of the most common conditions encountered in dermatology and affects individuals across all racial and ethnic groups.1 However, there is little known regarding variation in response…

INTRODUCTION Psoriasis is a systemic inflammatory disease effecting roughly 2% of the population.1,2 The effects of psoriatic skin disease have been shown to cause significant quality of life impairment equivalent…

INTRODUCTIONIn clinical trials, the placebo has an essential role as a comparison set point for various therapies and drugs. Moreover, the placebo response ultimately determines how randomized controlled trials are…

INTRODUCTION Atopic dermatitis (AD) or eczema is a common inflammatory skin disease with a relapsing remitting course. Clinically, it is marked by xerosis and prutitus.1 Current estimates suggest that up…